SCHEMBL19737555

SCHEMBL19737555

O=S(=O)(c1ccc(F)cc1)n1cc(-c2ccccc2)c2cc(O)ccc21

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 15/20 0.59
L3MBTL1 Q9Y468 1/20 0.56
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
ELAVL1 Q15717 1/20 0.51
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
ESR1 P03372 1/20 0.44
ESRRA P11474 1/20 0.44
ESR2 Q92731 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19737507 0.91 HTR6 (0.71) HTR6L3MBTL1CA12CA1CA2
SCHEMBL19737480 0.88 HTR6 (0.56) HTR6L3MBTL1CA12CA1CA2
SCHEMBL19737373 0.88 HTR6 (0.59) HTR6L3MBTL1CA12CA1CA2
Dimethylamine SCHEMBL21222481 0.86 HTR6 (0.64) HTR6L3MBTL1CA12CA1CA2
SCHEMBL21222635 0.84 HTR6 (0.55) HTR6L3MBTL1CA12CA1CA2
SCHEMBL21233248 0.83 HTR6 (0.56) HTR6L3MBTL1CA12CA1CA2
SCHEMBL19737629 0.82 HTR6 (0.58) HTR6L3MBTL1CYP3A4CYP2D6HTR2A
SCHEMBL19737377 0.80 HTR6 (0.59) HTR6L3MBTL1CA12CA1CA2
SCHEMBL19737552 0.80 HTR6 (0.55) HTR6L3MBTL1CA12CA1CA2
SCHEMBL19737475 0.79 TNFSF11 (0.52) HTR6L3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 US disclosed
WO-2017216732-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY AZI2, TPMT, TYMS HTR6 1922/4885L3MBTL1 4885/4885CA12 3782/4885
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS HTR6 1922/4885L3MBTL1 4885/4885CA12 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.